The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Changes in molecular profile following platinum chemotherapy in NSCLC.
W. Huang
No relevant relationships to disclose
M. Skokan
No relevant relationships to disclose
Y. Chang
No relevant relationships to disclose
C. Wu
No relevant relationships to disclose
J. Lee
No relevant relationships to disclose
W. Feser
No relevant relationships to disclose
A. E. BarĂ³n
No relevant relationships to disclose
P. A. Bunn
Consultant or Advisory Role - Abraxis BioScience; Allos Therapeutics; Amgen; AstraZeneca; Bayer; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lilly; Novartis; OSI Pharmaceuticals; Poniard Pharmaceuticals; Roche; Sanofi ; Syndax
Stock Ownership - Merrimack
Honoraria - Lilly
Other Remuneration - Patent on anti-EGFR+HDAC therapy; Patent on EGFR FISH testing
M. Varella-Garcia
Consultant or Advisory Role - Abbott Molecular
Honoraria - Abbott Molecular (I)
Other Remuneration - Roche